MedKoo Cat#: 414841 | Name: Pemirolast Na

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pemirolast Na is an Antiallergic drug.

Chemical Structure

Pemirolast Na
Pemirolast Na
CAS#69372-22-1 (Na)

Theoretical Analysis

MedKoo Cat#: 414841

Name: Pemirolast Na

CAS#: 69372-22-1 (Na)

Chemical Formula: C10H7N6NaO

Exact Mass:

Molecular Weight: 250.19

Elemental Analysis: C, 48.01; H, 2.82; N, 33.59; Na, 9.19; O, 6.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
69372-19-6 (free base); 100299-08-9 (potassium); 69372-22-1 (Na)
Synonym
Pemirolast sodium; Pemirolast Na; BMY2651731; BMY 2651731; BMY-2651731
IUPAC/Chemical Name
4H-Pyrido(1,2-a)pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, sodium salt (1:1)
InChi Key
KYIZZXKWRKKFSQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H7N6O.Na/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1
SMILES Code
O=C1C(C2=N[N-]N=N2)=CN=C3N1C=CC=C3C.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 250.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Pemirolast. 2018 Dec 3. PMID: 30000745. 2: Tatsushima Y, Egashira N, Matsushita N, Kurobe K, Kawashiri T, Yano T, Oishi R. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62. doi: 10.1016/j.ejphar.2011.04.026. Epub 2011 Apr 27. PMID: 21539837. 3: Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL; Pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther. 2002 Oct;18(5):475-88. doi: 10.1089/10807680260362759. PMID: 12419098. 4: Itoh Y, Sendo T, Hirakawa T, Takasaki S, Goromaru T, Nakano H, Oishi R. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology. 2004 May;46(6):888-94. doi: 10.1016/j.neuropharm.2003.11.018. PMID: 15033348. 5: Yahata H, Saito M, Sendo T, Itoh Y, Uchida M, Hirakawa T, Nakano H, Oishi R. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int J Cancer. 2006 May 15;118(10):2636-8. doi: 10.1002/ijc.21680. PMID: 16353140. 6: Gohda T, Ra C, Hamada C, Tsuge T, Kawachi H, Tomino Y. Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. Arzneimittelforschung. 2008;58(1):18-23. doi: 10.1055/s-0031-1296461. PMID: 18368946. 7: Minami K, Hossen MA, Kamei C. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. Biol Pharm Bull. 2005 Mar;28(3):473-6. doi: 10.1248/bpb.28.473. PMID: 15744071. 8: Kawashima T, Iwamoto I, Nakagawa N, Tomioka H, Yoshida S. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Immunol. 1994;103(4):405-9. doi: 10.1159/000236662. PMID: 8130655. 9: Ohsawa H, Noike H, Kanai M, Yoshinuma M, Mineoka K, Hitsumoto T, Aoyagi K, Sakurai T, Sato S, Uchi T, Kawamura K, Tokuhiro K, Uchida Y, Tomioka H. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1998 Dec;136(6):1081-7. doi: 10.1016/s0002-8703(98)70167-x. PMID: 9842024. 10: Shulman DG. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study. Adv Ther. 2003 Jan-Feb;20(1):31-40. doi: 10.1007/BF02850117. PMID: 12772816.